References
1. Lang E, Kapila A, Shlugman D, Hoke JF, Sebel PS, Glass PSA. Reduction of Isoflurane Minimal Alveolar Concentration by Remifentanil. Anesthesiology 1996; 85: 721-28.
2. McNicol ED, Ferguson MC, Hudcova J. Patient controlled opioid analgesia versus non-patient controlled opioid analgesia for postoperative pain. Cochrane Database Syst Rev 2015; 2015: CD003348-CD48.
3. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schüttler J. Differential Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by S -Ketamine and Clonidine in Humans. Anesthesiology 2003; 99: 152-59.
4. Minville V, Fourcade O, Girolami JP, Tack I. Opioid-induced hyperalgesia in a mice model of orthopaedic pain: preventive effect of ketamine†. British Journal of Anaesthesia 2010; 104: 231-38.
5. Vinik HR, Kissin I. Rapid Development of Tolerance to Analgesia During Remifentanil Infusion in Humans. Anesthesia & Analgesia 1998; 86: 1307-11.
6. Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. British Journal of Anaesthesia 2014; 112: 991-1004.
7. He W, Wu Z, Zu L, Sun H, Yang X. Application of erector spinae plane block guided by ultrasound for postoperative analgesia in breast cancer surgery: A randomized controlled trial. Cancer Communications 2020; 40: 122-25.
8. Shafi S, Collinsworth AW, Copeland LA, Ogola GO, Qiu T, Kouznetsova M, Liao I-C, Mears N, Pham AT, Wan GJ, Masica AL. Association of Opioid-Related Adverse Drug Events With Clinical and Cost Outcomes Among Surgical Patients in a Large Integrated Health Care Delivery System. JAMA Surgery 2018; 153: 757-63.
9. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14: 145-61.
10. Guntz E, Dumont H, Roussel C, Gall D, Dufrasne F, Cuvelier L, Blum D, Schiffmann Serge N, Sosnowski M. Effects of Remifentanil on N -methyl-d-aspartate Receptor: An Electrophysiologic Study in Rat Spinal Cord. Anesthesiology 2005; 102: 1235-41.
11. Zhao M, Joo Daisy T. Enhancement of Spinal N -Methyl-d-aspartate Receptor Function by Remifentanil Action at δ-Opioid Receptors as a Mechanism for Acute Opioid-induced Hyperalgesia or Tolerance. Anesthesiology 2008; 109: 308-17.
12. Chu LF, Angst MS, Clark D. Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations. The Clinical Journal of Pain 2008; 24: 479-96.
13. Wu L, Huang X, Sun L. The efficacy of N-methyl-d-aspartate receptor antagonists on improving the postoperative pain intensity and satisfaction after remifentanil-based anesthesia in adults: a meta-analysis. Journal of Clinical Anesthesia 2015; 27: 311-24.
14. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Annals of Internal Medicine 2015; 162: 777-84.
15. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Statistical Methods in Medical Research 2018; 27: 1785-805.
16. Apfel Christian C, Läärä E, Koivuranta M, Greim C-A, Roewer N. A Simplified Risk Score for Predicting Postoperative Nausea and Vomiting : Conclusions from Cross-validations between Two Centers. Anesthesiology 1999; 91: 693-93.
17. Eberhart LHJ, Mauch M, Morin AM, Wulf H, Geldner G. Impact of a multimodal anti-emetic prophylaxis on patient satisfaction in high-risk patients for postoperative nausea and vomiting. Anaesthesia 2002; 57: 1022-27.
18. Myles PS, Williams DL, Hendrata M, Anderson H, Weeks AM. Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. British Journal of Anaesthesia 2000; 84: 6-10.
19. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
20. White IR. Multivariate Random-effects Meta-regression: Updates to Mvmeta. The Stata Journal 2011; 11: 255-70.
21. Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013; 8: e76654-e54.
22. van Valkenhoef G, Dias S, Ades AE, Welton NJ. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Research Synthesis Methods 2016; 7: 80-93.
23. Mao J, Price D, Mayer D. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. The Journal of Neuroscience 1994; 14: 2301-12.
24. Mao J, Sung B, Ji R-R, Lim G. Chronic Morphine Induces Downregulation of Spinal Glutamate Transporters: Implications in Morphine Tolerance and Abnormal Pain Sensitivity. The Journal of Neuroscience 2002; 22: 8312-23.
25. Zhao Y-L, Chen S-R, Chen H, Pan H-L. Chronic Opioid Potentiates Presynaptic but Impairs Postsynaptic N-Methyl-d-aspartic Acid Receptor Activity in Spinal Cords: IMPLICATIONS FOR OPIOID HYPERALGESIA AND TOLERANCE*. Journal of Biological Chemistry 2012; 287: 25073-85.
26. Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem 2012; 11: 52-64.
27. Baba H, Kohno T, Moore KA, Woolf CJ. Direct Activation of Rat Spinal Dorsal Horn Neurons by Prostaglandin E2. The Journal of Neuroscience 2001; 21: 1750-56.
28. O’Rielly Darren D, Loomis Christopher W. Increased Expression of Cyclooxygenase and Nitric Oxide Isoforms, and Exaggerated Sensitivity to Prostaglandin E2, in the Rat Lumbar Spinal Cord 3 Days after L5–L6 Spinal Nerve Ligation. Anesthesiology 2006; 104: 328-37.
29. Malmberg A, Yaksh T. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276-79.
30. Yaksh TL, Malmberg AB. Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products. Agents Actions Suppl 1993; 41: 89-100.
31. Li QB, Chang L, Ye F, Luo QH, Tao YX, Shu HH. Role of spinal cyclooxygenase-2 and prostaglandin E2 in fentanyl-induced hyperalgesia in rats. British Journal of Anaesthesia 2018; 120: 827-35.
32. Peng Y, Zang T, Zhou L, Ni K, Zhou X. COX-2 contributed to the remifentanil-induced hyperalgesia related to ephrinB/EphB signaling. Neurological Research 2019; 41: 519-27.
33. Koppert W, Wehrfritz A, Körber N, Sittl R, Albrecht S, Schüttler J, Schmelz M. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. PAIN 2004; 108: 148-53.
34. Lenz H, Raeder J, Draegni T, Heyerdahl F, Schmelz M, Stubhaug A. Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. PAIN 2011; 152: 1289-97.
35. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions. PAIN 1995; 62: 259-74.
36. Guay DRP. Pregabalin in neuropathic pain: A more “pharmaceutically elegant” gabapentin? The American Journal of Geriatric Pharmacotherapy 2005; 3: 274-87.
37. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl 6: 13-8.
38. Chizh BA, Göhring M, Tröster A, Quartey GK, Schmelz M, Koppert W. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers†. British Journal of Anaesthesia 2007; 98: 246-54.
39. Field MJ, Bramwell S, Hughes J, Singh L. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? PAIN 1999; 83: 303-11.
40. Lederer AJ, Bornemann-Cimenti H, Wejbora M, Kern-Pirsch C, Michaeli K, Sandner-Kiesling A. Pregabalin und postoperative Hyperalgesie. Der Schmerz 2011; 25: 12-18.
41. Stoicea N, Russell D, Weidner G, Durda M, Joseph NC, Yu J, Bergese SD. Opioid-induced hyperalgesia in chronic pain patients and the mitigating effects of gabapentin. Frontiers in Pharmacology 2015; 6.
42. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonistsTheir pharmacology and therapeutic role. Anaesthesia 1999; 54: 146-65.
43. Zheng Y, Cui S, Liu Y, Zhang J, Zhang W, Zhang J, Gu X, Ma Z. Dexmedetomidine prevents remifentanil-induced postoperative hyperalgesia and decreases spinal tyrosine phosphorylation of N-methyl-d-aspartate receptor 2B subunit. Brain Research Bulletin 2012; 87: 427-31.
44. Yuan Y, Sun Z, Chen Y, Zheng Y, Xie K-L, He Y, Wang Z, Wang G-L, Yu Y-H. Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro. PLoS One 2017; 12: e0171348-e48.
45. Le Bot A, Michelet D, Hilly J, Maesani M, Dilly MP, Brasher C, Mantz J, Dahmani S. Efficacy of intraoperative dexmedetomidine compared with placebo for surgery in adults: a meta-analysis of published studies. Minerva Anestesiol 2015; 81: 1105-17.
46. Jin S, Liang DD, Chen C, Zhang M, Wang J. Dexmedetomidine prevent postoperative nausea and vomiting on patients during general anesthesia: A PRISMA-compliant meta analysis of randomized controlled trials. Medicine 2017; 96: e5770.
47. Grape S, Kirkham KR, Frauenknecht J, Albrecht E. Intra-operative analgesia with remifentanil vs. dexmedetomidine: a systematic review and meta-analysis with trial sequential analysis. Anaesthesia 2019; 74: 793-800.
48. Gan TJ, Belani KG, Bergese S, Chung F, Diemunsch P, Habib AS, Jin Z, Kovac AL, Meyer TA, Urman RD, Apfel CC, Ayad S, Beagley L, Candiotti K, Englesakis M, Hedrick TL, Kranke P, Lee S, Lipman D, Minkowitz HS, Morton J, Philip BK. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesthesia & Analgesia 2020; 131: 411-48.
49. Aouad MT, Zeeni C, Al Nawwar R, Siddik-Sayyid SM, Barakat HB, Elias S, Yazbeck Karam VG. Dexmedetomidine for Improved Quality of Emergence From General Anesthesia: A Dose-Finding Study. Anesthesia & Analgesia 2019; 129: 1504-11.
50. Duan X, Coburn M, Rossaint R, Sanders RD, Waesberghe JV, Kowark A. Efficacy of perioperative dexmedetomidine on postoperative delirium: systematic review and meta-analysis with trial sequential analysis of randomised controlled trials. British Journal of Anaesthesia 2018; 121: 384-97.
51. Kaye AD, Chernobylsky DJ, Thakur P, Siddaiah H, Kaye RJ, Eng LK, Harbell MW, Lajaunie J, Cornett EM. Dexmedetomidine in Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain. Curr Pain Headache Rep 2020; 24: 21-21.
52. Bao N, Tang B. Organ-Protective Effects and the Underlying Mechanism of Dexmedetomidine. Mediators Inflamm 2020; 2020: 6136105-05.
53. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clinical Pharmacokinetics 2017; 56: 893-913.
54. Comelon M, Raeder J, Stubhaug A, Nielsen CS, Draegni T, Lenz H. Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia† †This Article is accompanied by Editorial Aew050. British Journal of Anaesthesia 2016; 116: 524-30.
55. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. American Journal of Hospice and Palliative Medicine® 2005; 22: 291-94.
56. Rivat C, Bollag L, Richebé P. Mechanisms of regional anaesthesia protection against hyperalgesia and pain chronicization. Current Opinion in Anesthesiology 2013; 26: 621-25.